|
NXP900 Clinical Trials
3 actively recruiting trials across 3 locations
▲ +1 trial since August 2026
Pipeline
Phase 1: 3
Top Sponsors
- Nuvectis Pharma, Inc.3
Indications
- Lung Cancer3
- Cancer3
- ALK Positive1
- ALK+ Non-Small-Cell Lung Carcinoma1
- Non-small Cell Lung Adenocarcinoma1
Phoenix, Arizona1 trial
Phase 1
Calverton, Maryland1 trial
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Maryland Oncology Hematology
Phase 1
Fairfax, Virginia1 trial
Study of NXP900 With Lorlatinib in ALK+ Lung Cancer
NEXT Virginia
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.